This observational study is looking at how a medication called CFTR modulators (specifically ETI) affects blood sugar levels in people with Cystic Fibrosis Related Diabetes (CFRD). Researchers want to see if ETI improves how your body handles sugar, especially after eating. You might be able to join if you are between 21 and 75 years old, have CFRD, and meet certain health requirements like specific creatinine and HbA1c levels. The study will compare people with CFRD who are taking ETI to those who are not. Success in this study would mean seeing an improvement in something called the Disposition Index (DI) in those taking ETI. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design

This is an observational study with a planned enrollment of 30 participants. It compares individuals with CFRD who are on CFTR modulator (ETI) therapy to those who are not.

What's involved

You will undergo a single mixed meal tolerance test (MMTT) on Day 1. This test involves eating a meal and then having several measurements taken to understand your glucose and insulin levels.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Disposition Index, is measured at Day 1 during the mixed meal test. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.